Press release
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Forecast - FDA Approvals, Nanomedicine & Clinical Developments
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market
The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment market was valued at US$ 1.67 billion in 2023 and is projected to reach US$ 7.64 billion by 2031, growing at a compound annual growth rate (CAGR) of 21.8% during the forecast period 2024-2031.
Market Overview
Metabolic Dysfunction-Associated Steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is an advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by liver inflammation and damage due to fat accumulation, often linked to obesity and diabetes. The market includes drugs like Rezdiffra, therapies such as phytic acid-based nanomedicine, and lifestyle interventions like weight management and diabetes control. It serves hospitals, specialty clinics, and homecare settings. The market is driven by the rising prevalence of MASLD, technological advancements, and increasing clinical trials, though high costs and regulatory hurdles pose challenges.
📌 Access valuable insights with our sample report - (Please enter your Corporate Email ID to get priority access):- https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-treatment-market?rk
Market Opportunities
Key opportunities include developing novel therapeutics like nanomedicine and GLP-1 receptor agonists, expanding treatment access in emerging markets, and leveraging AI for drug discovery. Increasing focus on combination therapies and early diagnosis through non-invasive biomarkers also presents significant growth potential.
Key Trends
Emergence of novel drugs like Rezdiffra and pegozafermin for MASH treatment.
Growing adoption of nanomedicine and anti-inflammatory therapies.
Rising focus on lifestyle interventions alongside pharmacological treatments.
Recent Developments
March 2024: The FDA approved Rezdiffra, the first drug for MASH, developed by Madrigal Pharmaceuticals, marking a milestone in treatment options.
May 2024: 89bio initiated the Phase III ENLIGHTEN-Cirrhosis trial for pegozafermin in MASH patients with compensated cirrhosis.
June 2024: Eli Lilly's Phase II SYNERGY-NASH study reported over 50% of patients on tirzepatide achieved MASH resolution without fibrosis worsening.
August 2024: Altimmune's Phase I trial for pemvidutide showed significant reductions in liver fat and inflammation, with Phase 2b IMPACT trial ongoing.
July 2024: Research from Northwestern Polytechnical University highlighted phytic acid-based nanomedicine's potential for MASH therapy due to its antioxidant and anti-inflammatory properties.
Market Dynamics: Drivers
Increasing Prevalence of MASLD
The rising global prevalence of MASLD, affecting 30% of adults worldwide (nih.gov), is a major driver. MASH, found in 63% of MASLD patients undergoing liver biopsy in Asian cohorts, is associated with severe fibrosis and increased liver-related mortality. In the U.S., MASH is a leading cause of liver transplantation, with its burden projected to grow due to rising obesity and diabetes rates, fueling demand for effective treatments.
Market Dynamics: Restraints
High Costs and Regulatory Challenges
High treatment costs, lack of awareness, and stringent regulatory requirements for drug approvals hinder market growth. The complex approval process for novel MASH therapies, requiring extensive clinical trials to demonstrate safety and efficacy, delays market entry and increases development costs, particularly for smaller manufacturers.
📌 Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-treatment-market
Market Segment Analysis
By Treatment: Drugs Dominate
The drug segment held a 54.3% market share in 2024, driven by the FDA approval of Rezdiffra (March 2024), the first drug for MASH, which achieved MASH resolution and fibrosis improvement in Phase 3 trials. Ongoing trials for drugs like pegozafermin and pemvidutide further bolster this segment's dominance.
By End-User
Hospitals and specialty clinics lead due to their role in advanced diagnostics and treatment, while homecare is growing with the rise of patient-centric care models.
By Region
North America dominates, while Asia-Pacific is the fastest-growing region due to rising obesity rates and healthcare investments.
Geographical Share
North America Holds Significant Share
North America accounted for a 43.2% market share in 2024, driven by high MASLD prevalence, advanced healthcare infrastructure, and significant R&D investments. Key developments, such as Eli Lilly's Phase II SYNERGY-NASH study (June 2024) showing tirzepatide's efficacy and 89bio's Phase III ENLIGHTEN-Cirrhosis trial (May 2024), underscore the region's leadership.
Asia-Pacific Grows Rapidly
Asia-Pacific is the fastest-growing region, driven by increasing obesity, diabetes, and MASLD prevalence, particularly in China and India. Investments in healthcare infrastructure and clinical research support rapid market expansion.
📌 Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-treatment-market
Major Players
Key companies in the MASH treatment market include:
Madrigal Pharmaceuticals
Simson Pharma Limited
Dr. Reddy's Laboratories Ltd.
Thermo Fisher Scientific Inc.
Biosynth
Affgility Solutions
Conscientia Industrial Co. Ltd.
Smolecule Inc.
89bio Inc.
Sandoo Pharmaceuticals and Chemicals Co. Ltd.
📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Forecast - FDA Approvals, Nanomedicine & Clinical Developments here
News-ID: 4172044 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Glaucoma Market to Reach $12.77 Billion by 2031 | Driven by Aging Population & F …
The global glaucoma market was valued at US$ 8.36 billion in 2023 and is projected to reach US$ 12.77 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period 2024-2031.
Market Overview
Glaucoma is a group of eye conditions causing progressive vision loss and blindness due to optic nerve damage, primarily from elevated intraocular pressure (IOP) caused by aqueous humor buildup. The market encompasses treatments…
Decentralized clinical trials Market Outlook 2025-2033: $8.68B to $29.9B Growth …
The global decentralized clinical trials (DCTs) market was valued at US$ 8.68 billion in 2024 and is projected to reach US$ 29.90 billion by 2033, growing at a compound annual growth rate (CAGR) of 14.8% during the forecast period 2025-2033.
Market Overview
Decentralized clinical trials (DCTs) leverage digital technologies such as telemedicine, wearable sensors, and electronic data capture (EDC) systems to conduct clinical research remotely, reducing the need for in-person site visits.…
Digital Holographic Microscopy Market Growth Driven by Pharma & Biotechnology-US …
The Digital Holographic Microscopy (DHM) market is witnessing a transformative phase, driven by the increasing demand for advanced, non-invasive imaging technologies across scientific and industrial applications. DHM, an innovative optical microscopy technique, leverages holography principles to capture high-resolution, three-dimensional images of microscopic objects without the need for staining or labeling.
This capability makes it invaluable for real-time observation of live cells, material surfaces, and microstructures, positioning DHM as a cornerstone…
North America Intravascular Ultrasound Systems Market Led by U.S. Dominance, CAG …
The North America Intravascular Ultrasound (IVUS) Systems Market is a dynamic and rapidly evolving segment of the medical imaging industry, driven by the increasing demand for advanced diagnostic tools in cardiovascular care. Intravascular ultrasound is a cutting-edge imaging technology that utilizes ultrasound waves to provide high-resolution, cross-sectional images of blood vessels, particularly coronary arteries. This technology is pivotal in interventional cardiology, offering detailed visualization of vessel walls, lumen, and plaque…
More Releases for MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epid …
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly referred to as Non-Alcoholic Steatohepatitis (NASH), is a progressive form of fatty liver disease characterized by fat accumulation, inflammation, hepatocyte injury, and varying degrees of fibrosis. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to…
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Pepper Mash Market Size Estimated to grow USD 0.517 Billion by 2032
Pepper Mash Market Overview
The pepper mash market is a dynamic segment of the global food industry, characterized by its rich flavor profiles and wide-ranging applications. Pepper mash, a key ingredient in the production of hot sauces, seasonings, and processed foods, has gained significant traction due to its ability to impart heat and complexity to various dishes. This blog delves into the market overview, competitive landscape, key drivers, segmentation, and regional…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
